Four years into a diabetes management routine, the plan a client enrolled in during their first AEP is rarely the right plan for this one. The formulary changed. The specialty tier moved. The network dropped the endocrinologist. Metal tier tells you the cost-sharing shape; it does not tell you whether the plan covers the medications keeping the client out of the ER.
Legacy quoting platforms built for enterprise group benefits, the category Connecture dominated before the market shifted, were not designed around individual ACA formulary lookup. The broker had to go to the plan website separately, search the drug list manually, and hope the tier data matched what the plan would actually apply at the pharmacy counter. The checklist below is what a broker working chronic-condition households needs to run before a recommendation goes out.
Key Takeaways
- Confirm formulary tier and cost-sharing for each active prescription before recommending a plan.
- Step therapy requirements for GLP-1s and biologics are standard on most ACA formularies.
- Run a prior authorization check on every specialty drug before the client enrolls.
- The OOPM break-even analysis identifies whether a Gold plan pays for itself for a high-utilization client.
- Network continuity for existing specialists is a separate confirmation from the formulary check.
Step 1: Pull the formulary for each plan under consideration
ACA plan formularies are published documents, updated at minimum each plan year and sometimes mid-year for generic substitutions. Every plan on Healthcare.gov links to a formulary; every state-based exchange provides the same. The document lists each covered drug, its formulary tier, and any utilization management requirements.
For a client with three active prescriptions, the broker needs to confirm three lookups, not one. A plan that covers metformin generously and places semaglutide in Tier 4 at 30% coinsurance has a very different cost profile than a plan that places both in preferred tiers. The comparison only becomes visible when all three medications are checked against each plan's published formulary.
| Formulary tier | Drug type | Typical cost-sharing | Broker action |
|---|---|---|---|
| Tier 1 — Generic | Metformin, lisinopril, most generics | $0 to $10 copay; often $0 pre-deductible on Silver | Confirm tier; no PA typical |
| Tier 2 — Preferred brand | Some branded insulins, preferred statins | $20 to $60 copay after deductible | Confirm tier; check step therapy |
| Tier 3 — Non-preferred brand | Off-formulary brands with generic available | $50 to $150 copay or 30–40% coinsurance | Consider generic equivalent; check PA |
| Tier 4 — Specialty | GLP-1 drugs, biologics, infusion therapy | 25–35% coinsurance up to OOPM | PA required; step therapy common; run OOPM break-even |
| Tier 5 — Preferred specialty | Some plans carve out preferred specialty at lower cost-sharing | 20–25% coinsurance; slightly better than Tier 4 | Verify against Tier 4; check if drug qualifies |
Illustrative examples. Actual tier placement and cost-sharing depend on the specific plan and plan year. Confirm against the plan formulary before advising.
Step 2: Check for step therapy and prior authorization requirements
Step therapy and prior authorization (PA) are the two most common reasons a client fills a medication for three years, switches to a new plan in January, and gets a rejection at the pharmacy on January 3rd. They are also the two most common reasons a broker gets a frustrated call in the first week of coverage.
Step therapy means the plan requires documented failure of a lower-cost alternative before it will cover the prescribed drug. For GLP-1 medications prescribed for Type 2 diabetes management, step therapy protocols typically require evidence that the client trialed metformin and at least one other oral agent. A client who has managed diabetes with semaglutide for two years still needs to meet that protocol on a new plan, unless the prescribing physician submits a step therapy exception with clinical justification.
Prior authorization requirements appear in the formulary alongside the drug. If the formulary shows "PA" next to a medication, the broker should tell the client to contact their physician before January 1st to initiate the PA submission. Plans process PAs within 72 hours for routine requests and 24 hours for urgent clinical situations, but the documentation burden falls on the physician's office, and practices that are busy in late December may not complete submissions before coverage starts.
Step 3: Run the OOPM break-even analysis for high-utilization clients
The out-of-pocket maximum break-even analysis is the comparison a broker should run before recommending a Gold plan to a client who will predictably use significant healthcare services during the plan year. The math is straightforward.
Example: a 52-year-old managing rheumatoid arthritis with quarterly infusions and regular specialist visits. A Silver plan costs $480 per month in premium ($5,760 annually); a Gold plan costs $620 per month ($7,440 annually). The Silver OOPM is $7,500; the Gold OOPM is $4,500. The premium difference is $1,680. The OOPM difference is $3,000. If the client reaches the OOPM on both plans, Gold saves $1,320 net over the plan year. If the client reaches $5,000 in cost-sharing, Gold still saves about $700 net. The break-even is around $2,200 in total cost-sharing incurred.
For a client with predictable infusion therapy, the analysis usually points clearly at Gold or Platinum. For a client with variable utilization, the broker should present the two scenarios and let the client decide based on risk tolerance.
Step 4: Confirm network continuity for existing specialists
A client managing a chronic condition with an established specialist relationship has two coverage risks: the drug and the doctor. A plan can cover the medication and still exclude the specialist prescribing it from its network. In a narrow-network Silver plan, that is a realistic scenario, not an edge case.
The network check requires a different lookup than the formulary. Each plan's provider directory (searchable on Healthcare.gov or the plan's own website) shows which physicians are in-network. For a client seeing a rheumatologist, endocrinologist, or oncologist, the broker should confirm the specialist is in-network on any plan being recommended. If the client's specialist is only in-network on one plan option, that plan wins the recommendation regardless of premium, unless the specialist is willing to apply for in-network status or the client is willing to change providers.
Step 5: Document the recommendation rationale
For clients with chronic conditions, the plan recommendation should be documented with the checklist results. If a client later claims the broker failed to account for their drug costs or network access, the documentation of the formulary check, PA status, and OOPM analysis is the broker's record of due diligence.
The documentation does not need to be elaborate: a note in the client file showing the formulary tier for each active medication, any PA or step therapy flags identified, and the OOPM break-even comparison is sufficient. The value of the note is not compliance theater; it is the record of what the broker actually checked before the recommendation was made.
Questions about ACA plan selection for clients with chronic conditions
Formulary tiers, step therapy, prior authorization, and OOPM analysis for brokers serving high-utilization households.
What is the most important factor when selecting an ACA plan for a client with a chronic condition?
Drug formulary coverage is typically the highest-stakes factor for clients managing a chronic condition with prescription medications. A plan that places a client's maintenance drug in a specialty tier can generate thousands of dollars in annual out-of-pocket costs even on a Gold or Platinum plan. Brokers should pull the specific plan formulary, identify the tier placement for each active prescription, and calculate the annual cost-sharing before comparing premiums.
How do ACA drug formulary tiers work and how do they affect out-of-pocket costs?
ACA formularies typically run five tiers: generic (Tier 1), preferred brand (Tier 2), non-preferred brand (Tier 3), specialty (Tier 4), and in some plans a specialty-plus or preferred specialty tier (Tier 5). Cost-sharing increases at each tier, with Tier 4 and Tier 5 drugs often subject to coinsurance rather than a flat copay, meaning the client pays a percentage of the drug cost until the OOPM is reached. A client on a biologic that a plan places in Tier 4 at 30% coinsurance on a drug with a $4,000 list price faces a very different monthly cost than a client whose generic metformin sits in Tier 1.
What is step therapy and how should brokers explain it to clients on specialty medications?
Step therapy requires that a patient try and fail a lower-cost drug before the plan authorizes coverage for the originally prescribed medication. On ACA plans, step therapy protocols for GLP-1 drugs, TNF inhibitors, and other biologics are common and can delay access to an established therapy for 60 to 90 days or longer while the required prior drugs are trialed. Brokers should explain this plainly: if the formulary shows a step therapy requirement, the client may need to request a step therapy exception with documentation from their physician before the plan will cover the drug they are already taking. Starting the exception process at enrollment, not after a pharmacy rejection, is the difference between a two-week delay and a two-month gap.
How does prior authorization work for GLP-1 drugs and biologics on ACA Marketplace plans?
Prior authorization (PA) on ACA plans is a plan-level determination separate from the formulary. A drug can appear on the formulary as covered and still require a PA submission before the first fill. For GLP-1 medications such as semaglutide prescribed for Type 2 diabetes management, PA requirements typically include a confirmed diabetes diagnosis, a documented HbA1c above a threshold, and sometimes evidence that prior medications were inadequate. Biologics for autoimmune conditions face similar requirements. Brokers should advise clients with existing PA approvals to confirm that a new plan will honor the determination or whether a new PA submission is required at plan start.
How does the OOPM break-even analysis work and when should brokers run it?
The OOPM break-even analysis compares the annual premium difference between two metal tiers against the difference in out-of-pocket maximum for a client expected to hit or approach the OOPM during the plan year. If a Gold plan costs $1,800 more in annual premium than a Silver plan but has a $2,500 lower OOPM, a client who expects to reach the cap saves $700 net by choosing Gold. The analysis is most useful for clients managing a condition requiring hospitalization, infusion therapy, or frequent specialist care. Clients with variable utilization, where reaching the OOPM is uncertain, need a second calculation showing the break-even utilization level.
